Keep Us Strong WikiLeaks logo

Currently released so far... 97115 / 251,287

Articles

Browse latest releases

Browse by creation date

Browse by origin

A B C D F G H I J K L M N O P Q R S T U V W Y Z

Browse by tag

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
ETRD EAGR ETTC EAID ECON EFIN ECIN EINV ELAB EAIR ENRG EPET EWWT ECPS EIND EMIN ELTN EC ETMIN EUC EZ ET ELECTIONS ENVR EU EUN EG EINT ER ECONOMICS ES EMS ENIV EEB EN ECE ECOSOC EK ENVIRONMENT EFIS EI EWT ENGRD ECPSN EXIM EIAD ERIN ECPC EDEV ENGY ECTRD EPA ESTH ECCT EINVECON ENGR ERTD EUR EAP EWWC ELTD EL EXIMOPIC EXTERNAL ETRDEC ESCAP ECO EGAD ELNT ECONOMIC ENV ETRN EIAR EUMEM ENRGPARMOTRASENVKGHGPGOVECONTSPLEAID EREL ECOM ECONETRDEAGRJA ETCC ETRG ECONOMY EMED ETR ENERG EITC EFINOECD EURM EENG ERA EXPORT ENRD ECONEINVETRDEFINELABETRDKTDBPGOVOPIC EGEN EBRD EVIN ETRAD ECOWAS EFTA ECONETRDBESPAR EGOVSY EPIN EID ECONENRG EDRC ESENV ETT EB ENER ELTNSNAR ECHEVARRIA ETRC EPIT EDUC ESA EFI ENRGY ESCI EE EAIDXMXAXBXFFR EETC ECIP EIAID EIVN EBEXP ESTN EING EGOV ETRA EPETEIND ELAN ETRDGK EAIDRW ETRDEINVECINPGOVCS EPEC ENVI ELN EAG EPCS EPRT EPTED ETRB EUM EAIDS EFIC EFINECONEAIDUNGAGM EAIDAR ESF EIDN ELAM EDU EV EAIDAF ECN EDA EXBS EINTECPS ENRGTRGYETRDBEXPBTIOSZ EPREL EAC EINVEFIN ETA EAGER EINDIR ECA ECLAC ELAP EITI EUCOM ECONEFINETRDPGOVEAGRPTERKTFNKCRMEAID EARG ELDIN EINVKSCA ENNP EFINECONCS EFINTS ECCP ETC EAIRASECCASCID EINN ETRP EAIDNI EFQ ECOQKPKO EGPHUM EBUD ECONEINVEFINPGOVIZ ENERGY ELB EINDETRD EMI ECONEFIN EIB EURN ETRDEINVTINTCS EIN EFIM ETIO ELAINE EMN EATO EWTR EIPR EINVETC ETTD ETDR EIQ ECONCS EPPD ENRGIZ EISL ESPINOSA ELEC EAIG ESLCO EUREM ENTG ERD EINVECONSENVCSJA EEPET EUNCH ECINECONCS ETRO ETRDECONWTOCS ECUN EFND EPECO EAIRECONRP ERGR ETRDPGOV ECPN ENRGMO EPWR EET EAIS EAGRE EDUARDO EAGRRP EAIDPHUMPRELUG EICN ECONQH EVN EGHG ELBR EINF EAIDHO EENV ETEX ERNG ED
KMDR KPAO KPKO KJUS KCRM KGHG KFRD KWMN KDEM KTFN KHIV KGIC KIDE KSCA KNNP KHUM KIPR KSUM KISL KIRF KCOR KRCM KPAL KWBG KN KS KOMC KSEP KFLU KPWR KTIA KSEO KMPI KHLS KICC KSTH KMCA KVPR KPRM KE KU KZ KFLO KSAF KTIP KTEX KBCT KOCI KOLY KOR KAWC KACT KUNR KTDB KSTC KLIG KSKN KNN KCFE KCIP KGHA KHDP KPOW KUNC KDRL KV KPREL KCRS KPOL KRVC KRIM KGIT KWIR KT KIRC KOMO KRFD KUWAIT KG KFIN KSCI KTFIN KFTN KGOV KPRV KSAC KGIV KCRIM KPIR KSOC KBIO KW KGLB KMWN KPO KFSC KSEAO KSTCPL KSI KPRP KREC KFPC KUNH KCSA KMRS KNDP KR KICCPUR KPPAO KCSY KTBT KCIS KNEP KFRDCVISCMGTCASCKOCIASECPHUMSMIGEG KNNB KGCC KINR KPOP KMFO KENV KNAR KVIR KDRG KDMR KFCE KNAO KDEN KGCN KICA KIMMITT KMCC KLFU KMSG KSEC KUM KCUL KMNP KSMT KCOM KOMCSG KSPR KPMI KRAD KIND KCRP KAUST KWAWC KTER KCHG KRDP KPAS KITA KTSC KPAOPREL KWGB KIRP KJUST KMIG KLAB KTFR KSEI KSTT KAPO KSTS KLSO KWNN KPOA KHSA KNPP KPAONZ KBTS KWWW KY KJRE KPAOKMDRKE KCRCM KSCS KWMNCI KESO KWUN KPLS KIIP KEDEM KPAOY KRIF KGICKS KREF KTRD KFRDSOCIRO KTAO KJU KWMNPHUMPRELKPAOZW KEN KO KNEI KEMR KKIV KEAI KWAC KRCIM KWCI KFIU KWIC KCORR KOMS KNNO KPAI KBWG KTTB KTBD KTIALG KILS KFEM KTDM KESS KNUC KPA KOMCCO KCEM KRCS KWBGSY KNPPIS KNNPMNUC KWN KERG KLTN KALM KCCP KSUMPHUM KREL KGH KLIP KTLA KAWK KWMM KVRP KVRC KAID KSLG KDEMK KX KIF KNPR KCFC KFTFN KTFM KPDD KCERS KMOC KDEMAF KMEPI KEMS KDRM KEPREL KBTR KEDU KNP KIRL KNNR KMPT KISLPINR KTPN KA KJUSTH KPIN KDEV KTDD KAKA KFRP KWNM KTSD KINL KJUSKUNR KWWMN KECF KWBC KPRO KVBL KOM KFRDKIRFCVISCMGTKOCIASECPHUMSMIGEG KEDM KFLD KLPM KRGY KNNF KICR KIFR KM KWMNCS KAWS KLAP KPAK KDDG KCGC KID KNSD KMPF KPFO KDP KCMR KRMS KNPT KNNNP KTIAPARM KDTB KNUP KPGOV KNAP KNNC KUK KSRE KREISLER KIVP KQ KTIAEUN KPALAOIS KRM KISLAO KWM KFLOA
PHUM PINR PTER PGOV PREL PREF PL PM PHSA PE PARM PINS PK PUNE PO PALESTINIAN PU PBTS PROP PTBS POL POLI PA PGOVZI POLMIL POLITICAL PARTIES POLM PD POLITICS POLICY PAS PMIL PINT PNAT PV PKO PPOL PERSONS PING PBIO PH PETR PARMS PRES PCON PETERS PRELBR PT PLAB PP PAK PDEM PKPA PSOCI PF PLO PTERM PJUS PSOE PELOSI PROPERTY PGOVPREL PARP PRL PNIR PHUMKPAL PG PREZ PGIC PBOV PAO PKK PROV PHSAK PHUMPREL PROTECTION PGOVBL PSI PRELPK PGOVENRG PUM PRELKPKO PATTY PSOC PRIVATIZATION PRELSP PGOVEAIDUKNOSWGMHUCANLLHFRSPITNZ PMIG PREC PAIGH PROG PSHA PARK PETER POG PHUS PPREL PS PTERPREL PRELPGOV POV PKPO PGOVECON POUS PGOVPRELPHUMPREFSMIGELABEAIDKCRMKWMN PWBG PMAR PREM PAR PNR PRELPGOVEAIDECONEINVBEXPSCULOIIPBTIO PARMIR PGOVGM PHUH PARTM PN PRE PTE PY POLUN PPEL PDOV PGOVSOCI PIRF PGOVPM PBST PRELEVU PGOR PBTSRU PRM PRELKPAOIZ PGVO PERL PGOC PAGR PMIN PHUMR PVIP PPD PGV PRAM PINL PKPAL PTERE PGOF PINO PHAS PODC PRHUM PHUMA PREO PPA PEPFAR PGO PRGOV PAC PRESL PORG PKFK PEPR PRELP PREFA PNG PGOVPHUMKPAO PRELECON PINOCHET PFOR PGOVLO PHUMBA PRELC PREK PHUME PHJM POLINT PGOVPZ PGOVKCRM PGOVE PHALANAGE PARTY PECON PEACE PROCESS PLN PRELSW PAHO PEDRO PRELA PASS PPAO PGPV PNUM PCUL PGGV PSA PGOVSMIGKCRMKWMNPHUMCVISKFRDCA PGIV PRFE POGOV PEL PBT PAMQ PINF PSEPC POSTS PHUMPGOV PVOV PHSAPREL PROLIFERATION PENA PRELTBIOBA PIN PRELL PGOVPTER PHAM PHYTRP PTEL PTERPGOV PHARM PROTESTS PRELAF PKBL PRELKPAO PKNP PARMP PHUML PFOV PERM PUOS PRELGOV PHUMPTER PARAGRAPH PERURENA PBTSEWWT PCI PETROL PINSO PINSCE PQL PEREZ PBS

Browse by classification

Community resources

courage is contagious

Viewing cable 06BRASILIA271, INTERFARMA BRIEFS CHARGE ON DIFFICULTIES IN DOING BUSINESS

If you are new to these pages, please read an introduction on the structure of a cable as well as how to discuss them with others. See also the FAQs

Understanding cables
Every cable message consists of three parts:
  • The top box shows each cables unique reference number, when and by whom it originally was sent, and what its initial classification was.
  • The middle box contains the header information that is associated with the cable. It includes information about the receiver(s) as well as a general subject.
  • The bottom box presents the body of the cable. The opening can contain a more specific subject, references to other cables (browse by origin to find them) or additional comment. This is followed by the main contents of the cable: a summary, a collection of specific topics and a comment section.
To understand the justification used for the classification of each cable, please use this WikiSource article as reference.

Discussing cables
If you find meaningful or important information in a cable, please link directly to its unique reference number. Linking to a specific paragraph in the body of a cable is also possible by copying the appropriate link (to be found at theparagraph symbol). Please mark messages for social networking services like Twitter with the hash tags #cablegate and a hash containing the reference ID e.g. #06BRASILIA271.
Reference ID Created Released Classification Origin
06BRASILIA271 2006-02-07 15:17 2011-07-11 00:00 UNCLASSIFIED//FOR OFFICIAL USE ONLY Embassy Brasilia
VZCZCXRO8629
RR RUEHRG
DE RUEHBR #0271/01 0381517
ZNR UUUUU ZZH
R 071517Z FEB 06
FM AMEMBASSY BRASILIA
TO RUEHC/SECSTATE WASHDC 4444
INFO RUEHSO/AMCONSUL SAO PAULO 6291
RUEHRG/AMCONSUL RECIFE 4287
RUEHRI/AMCONSUL RIO DE JANEIRO 1466
RUEHAC/AMEMBASSY ASUNCION 5206
RUEHBU/AMEMBASSY BUENOS AIRES 3768
RUEHLP/AMEMBASSY LA PAZ 4364
RUEHMN/AMEMBASSY MONTEVIDEO 6030
RUEHSG/AMEMBASSY SANTIAGO 5309
RUCPDO/USDOC WASHDC
UNCLAS SECTION 01 OF 03 BRASILIA 000271 
 
SIPDIS 
 
DEPT FOR EB/IPE SWILSON, AMADAMO AND WHA/BSC 
DEPT PLEASE PASS TO USTR MSULLIVAN, VESPINEL 
DEPT PLEASE PASS TO USPTO FOR JURBAN 
USDOC FOR 3134/USFCS/OIO/WH/EOLSON 
USDOC FOR 4332/ITA/MAC/WH/OLAC/MWARD 
NSC FOR SCRONIN 
AID/W FOR LAC/AA 
HHS FOR WSTEIGER 
 
SENSITIVE 
SIPDIS 
 
E.O. 12958: N/A 
TAGS: KIPR ETRD TBIO ECON BR
SUBJECT: INTERFARMA BRIEFS CHARGE ON DIFFICULTIES IN DOING BUSINESS 
IN BRAZIL 
 
REF:  2005 Brasilia 2729 (Notal) 
 
1.  (SBU)  Summary.  During a recent trip by Charge to Sao Paulo, 
officials from Interfarma - the local industry group representing 
international pharmaeuticals firms - described the challenges member 
companies face in operating in Brazil.  Chief among Interfarma 
complaints was that the high tax burden had lowered  pharmaceutical 
industry sales (and employment as well) and that the Brazilian 
government did not afford adequate protection to intellectual 
property rights (IPR).   Interfarma reps worried that legislation, 
currently in the Brazilian Chamber of Deputies, prohibiting the 
patenting of AIDs drugs might move forward to the Brazilian Senate. 
In a side conversation, the Brazil President of Merck told us that 
his company was in the process of negotiating with the Ministry of 
Health so as to avoid issuance of a compulsory license for that 
firm's anti-AIDs drugs; talks were proceeding smoothly. Finally, 
given their negative experiences in the 1990s with then-Minister of 
Health Jose Serra, company officials stated that they strongly 
preferred that the PSDB candidate opposing Lula in the upcoming 
presidential elections not be Serra - but instead Sao Paulo Governor 
Geraldo Alckmin.  End Summary. 
 
An Industry in Steady Decline 
----------------------------- 
 
2.  (SBU) On January 18, Charge, Sao Paulo Consul General, and 
various Consulate/Embassy officers received a briefing in Sao Paulo 
from Interfarma spokesmen.  Founded in 1990, Interfarma represents 
27 international pharmaceutical laboratories based in Brazil - with 
these companies accounting for 54% of the domestic pharmaceutical 
market.  Among the U.S. firms that are Interfarma members are 
Abbott, Merck, Eli Lilly, and Bristol-Myers Squibb.  Our 
interlocutors declared that all was not well in the Brazilian market 
as sales, in dollar terms, had declined since 1997 through 2004 
(from US$7.68 billion to US$5 billion) as had units sold (from 1.35 
billion to 1.32 billion).  In terms of relative rankings, Brazil had 
fallen from the 7th largest pharmaceutical market in the world in 
1998 to 13th in 2004 - just behind Mexico and Australia. 
 
3.  (SBU)  The principal reasons for the industry's decline, 
Interfarma reps told us, was the high value added taxes imposed by 
the government (18% just for the ICMS) and the high margin charged 
by retail pharmacies (28%).  When combined with freight costs, the 
cumulative effect of these fees/levies meant that for a drug sold 
wholesale by the industry for R$1, a prospective retail customer 
would pay R$2.08.  Worldwide, this compared to a 1.14 mark-up ratio 
in the United Kingdom, 1.44 in Mexico, 1.76 in Argentina, and 1.8 in 
Germany. (Note: this calculation reflects 2002 data.)  The high 
prevailing cost structure, Interfarma declared, had contributed 
greatly to the stagnation of the industry during recent years.  From 
1997 to 2004, both employment and investment had decline, from 
23,074 to 20,393 and from US$256 million to US$109 million, 
respectively.  Interfarma officials estimated that had conditions 
for doing business been better, over the past six years the industry 
could have generated over 15,000 new jobs and an additional US$2.2 
billion in fixed asset investment. 
 
Weak IPR Protection 
------------------- 
 
4. (SBU)  Yet another problem, we were told, was the government's 
lack of commitment to providing protection for intellectual 
property.  After the passage of the 1997 Industrial Property Law - 
which first allowed pharmaceuticals to be patented - the government 
had not adopted an investor-friendly regulatory stance. 
Specifically, industry officials complained that Article 229-C of 
the IPR law, added to the legislation in 1999, was 
TRIPs-inconsistent as it made the issuance of a pharmaceutical 
patent contingent upon prior approval by Brazil's drug regulatory 
agency (ANVISA).  ANVISA, they continued, while nominally 
independent in practice, was subservient to the Ministry of Health. 
The biggest problem, they felt, however, was that ANVISA and INPI 
(i.e., the patent agency) were just plain slow.  Out of 20,000 
 
BRASILIA 00000271  002 OF 003 
 
 
pharmaceutical patents applied for in 1996, the year after IPR law 
as enacted, to date only 149 had been approved. 
 
5. (SBU)  Our interlocutors opined that the situation could get 
worse if Sao Paulo Mayor Jose Serra received the PSDB presidential 
nomination and ended up beating Lula in the upcoming October 2006 
elections.  As Minister of Health during the previous Fernando 
Henrique Cardoso government, they said, Serra took a number of 
industry-unfriendly steps.  For instance, he was the driving force 
behind Article 229-C, he imposed retail price controls on 
pharmaceuticals, and he threatened the manufacturers of anti-AIDs 
drugs with compulsory licensing unless they lowered the prices they 
offered to Brazilian government purchasers.  Serra, they stated, was 
loathe to dialogue with the industry.  They much preferred the rival 
candidate for the PSDB nomination - Sao Paulo Governor Geraldo 
Alckmin. 
 
Bill 22 - the Biggest Challenge 
------------------------------- 
 
6. (SBU)  While our Interfarma contacts flagged a number of, in 
their view, objectionable bills currently pending in the Brazilian 
Congress, they made clear that the item which was receiving most of 
their attention was Bill 22 - a measure which, if enacted, would 
prohibit the patent of new anti-AIDs drugs.  Introduced by PT 
Federal Deputy Roberto Gouveia, the bill had already been approved 
by three lower house committees.  The bill was headed for debate (as 
yet unscheduled) on the lower house floor, although Interfarma 
lobbying had resulted in the creation of an additional hurdle: 
after the floor debate, it would need to pass through the Foreign 
Affairs committee prior to returning to the floor for a plenary 
vote.  Given popular sentiment in favor of the bill, Interfarma 
officials stated that it would be difficult to stop in the lower 
house. Its sponsor was a member of President Lula's party and the 
Speaker of the lower house had, on his own, previously introduced 
similar legislation.  Preparing for the worse, Interfarma was 
already reaching out to its Brazilian Senate contacts in an effort 
to stop the legislation there. 
 
7.  (SBU)  In response to Interfarma's request for assistance with 
respect to Bill 22, Charge stated that he would raise this issue 
with the Speaker of the Lower House the next time the two spoke.  In 
addition, Charge offered to host a strategy session with other 
affected embassies the next time Interfarma came to Brasilia to 
lobby the congress. 
 
Good News on Compulsory Licensing 
--------------------------------- 
 
8. (SBU)  In a side conversation with Merck's Brazil President, we 
were told that Merck's talks with the Ministry of Health regarding 
the GOB purchase of anti-AIDS pharmaceuticals were going well.  (See 
Reftel.)  The company had offered to co-produce its anti-retrovirals 
with government-owned labs, with any cost savings reaped being 
returned to the GOB in terms of lower prices.  Merck emphasized that 
this arrangement would not be a voluntary license.  The only 
problem, our Merck contact said, was that the GOB was slow in 
responding to Merck's proposal and if the Minister of Health ended 
up departing the cabinet in March to seek elective office, the talks 
might have to end up restarting from ground zero.  In post's 
continuing discussions with Gilead Science, the remaining U.S. 
pharmaceutical maker at risk, officials representing that company 
have expressed similar fears - while adding that the tenor of the 
talks to date had been positive. 
 
AVIAN FLU 
--------- 
 
9.  (U)  Finally, in response to a query from FCS Senior Commercial 
Officer, Interfarma officials stated that Brazil was well-situated 
with respect to a possible avian flu.  The GOB, they stated, was 
buying up the necessary stocks of anti-flu medicines. 
 
 
BRASILIA 00000271  003 OF 003 
 
 
CHICOLA